ストックスクリーナーアプリを入手
41.70
2.51%
1.05
前日終値:
$40.65
開ける：
$40.98
24時間の取引高:
251.76K
Relative Volume:
0.41
時価総額：
$2.40B
収益：
$45.48M
当期純損益:
$169.95M
株価収益率:
-15.56
EPS:
-2.68
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+1.54%
1か月 パフォーマンス:
-9.33%
6か月 パフォーマンス:
+31.41%
1年 パフォーマンス:
+140.03%
1日の値動き範囲:
$40.72
$43.38
1週間の範囲:
$33.31
$43.38
52週間の値動き範囲:
$16.80
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| PTGX | 41.68 | 2.40B | 45.48M | 169.95M | 230.85M | -2.68 |
| VRTX | 447.70 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.22 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Quest Partners LLC Increases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist takes center stage with Phase III fillip - The Pharma Letter
Protagonist Therapeutics' chief medical officer sells $78,107 in stock By Investing.com - Investing.com Australia
Protagonist Therapeutics' chief medical officer sells $78,107 in stock - Investing.com India
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data - BioCentury
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap DownHere's Why - MarketBeat
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - AccessWire
Protagonist Therapeutics to Unveil New Oral IL-17 Drug Candidate, Share Key Study Data | PTGX Stock News - StockTitan
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV
Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq
Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan
Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Amalgamated Bank Acquires 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
What is HC Wainwright’s Forecast for PTGX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for PTGX - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for PTGX - Defense World
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat
US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates - MSN
New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World
Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK
What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat
Protagonist Therapeutics Inc (PTGX) Q3 2024 Earnings: EPS Loss o - GuruFocus.com
Protagonist Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Joplin Globe
Protagonist (PTGX) Reports $583M Cash Position, Key Trial Results Due Q4 2024 | PTGX Stock News - StockTitan
Financial Enhancement Group LLC Purchases Shares of 41,818 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wedbush Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Wedbush Reiterates “Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4%Here's What Happened - MarketBeat
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Weatherford Democrat
Protagonist's Rusfertide Phase 2 Trial Results Set for Major ASH Meeting Reveal | PTGX Stock News - StockTitan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Vanguard Group Inc's Strategic Acquisition in Protagonist Therap - GuruFocus.com
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $52.83 - Defense World
State of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Louisiana State Employees Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 353% over 5 years despite pulling back 3.0% in the past week - Simply Wall St
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Allspring Global Investments Holdings LLC Buys 103,414 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ali Asif | Chief Financial Officer |
Sep 11 '24 |
Option Exercise |
15.68 |
12,000 |
188,160 |
46,960 |
| Ali Asif | Chief Financial Officer |
Sep 11 '24 |
Sale |
44.49 |
14,203 |
631,872 |
34,960 |
| Waddill William D. | Director |
Sep 10 '24 |
Option Exercise |
12.88 |
8,000 |
103,040 |
20,000 |
| Waddill William D. | Director |
Sep 10 '24 |
Sale |
45.00 |
8,000 |
360,000 |
12,000 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):